Eli Lilly and Company Stock price

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse 16:00:02 2023-12-05 EST Intraday chart for Eli Lilly and Company 5-day change 1st Jan Change
588.15 USD +0.42% -0.58% +60.77%
Sales 2023 * 33.6B 45.62B Sales 2024 * 38.84B 52.73B Capitalization 529B 718B
Net income 2023 * 5.29B 7.18B Net income 2024 * 10.69B 14.51B EV / Sales 2023 *
16,2x
Net Debt 2023 * 14.19B 19.27B Net Debt 2024 * 11.73B 15.92B EV / Sales 2024 *
13,9x
P/E ratio 2023 *
98,8x
P/E ratio 2024 *
48,2x
Employees 39,000
Yield 2023 *
0,74%
Yield 2024 *
0,88%
Free-Float 99.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.42%
1 week-0.58%
Current month-0.49%
1 month+3.58%
3 months+5.37%
6 months+32.39%
Current year+60.77%
More quotes
1 week
574.33
Extreme 574.33
601.97
1 month
574.33
Extreme 574.33
625.87
Current year
302.14
Extreme 302.14
629.97
1 year
302.14
Extreme 302.14
629.97
3 years
146.48
Extreme 146.48
629.97
5 years
101.36
Extreme 101.36
629.97
10 years
48.88
Extreme 48.88
629.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 1995
Director of Finance/CFO 50 2013
Compliance Officer - 1996
Members of the board TitleAgeSince
Director/Board Member 62 2021
Director/Board Member 67 2009
Director/Board Member 64 2004
More insiders
Date Price Change Volume
23-12-05 588.15 +0.42% 2,157,343
23-12-04 585.68 +0.28% 2,577,122
23-12-01 584.04 -1.18% 3,638,565
23-11-30 591.04 -0.14% 5,658,350
23-11-29 591.86 +0.04% 1,908,649

Delayed Quote Nyse, December 05, 2023 at 04:00 pm

More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (46.6%): products for treating osteoporosis, diabetes, and growth problems; - oncology (20.3%); - immunology diseases (11.8%); - neurology (6.7%): primarily drugs used in treating depression and schizophrenia; - other (14.6%). Net sales are distributed geographically as follows: the United States (59.4%), Europe (16.9%), Japan (8.3%), China (5.9%) and other (9.5%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
588.15USD
Average target price
619.14USD
Spread / Average Target
+5.27%
Consensus
1st Jan change Capi.
+60.77% 529 B $
+46.50% 444 B $
-10.25% 382 B $
-4.25% 269 B $
-10.54% 255 B $
-13.61% 231 B $
+1.76% 200 B $
-9.57% 198 B $
-43.23% 164 B $
+3.13% 145 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Eli Lilly and Company - Nyse
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits
fermer